5 Stocks to Watch: Week of 12/15/2025
Hope you’re enjoying the weekend. We did a little background work for the investing week ahead and unearthed 5 high-potential stocks for you, including:
- nVent Electric (NVT) rides 2 megatrends
- Amneal Pharmaceuticals (AMRX), our latest Stock of the Week…
- Eli Lilly & Co (LLY) is a Strong Buy despite a recent pullback
- MongoDB (MDB) just got a TON of analyst upgrades
- Kinross Gold Corp (KGC) is back on the list...
Let's get to it. (Missed last week's picks? Get them here.)
Note: Zen Ratings change daily. Be sure to check the ticker page of any stock to confirm its most up-to-date rating.
A note from our sponsors...
10 Best Stocks to Own in 2026 Enter your email address below and we'll send you MarketBeat's list of the 10 best stocks to own in 2026 and why they should be in your portfolio. You will also receive our free daily email newsletter with the latest buy and sell recommendations from Wall Street's top analysts. Get your copy now here1- nVent Electric PLC (NYSE: NVT)
nVent is riding two powerful megatrends at once — AI data center buildouts and global electrification — fueling growing demand across its critical infrastructure portfolio.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $109.10 — get current quote
Max 1-year forecast: $140.00
Why we're watching:
- Analyst support: NVT enjoys 7 Strong Buy and 1 Buy rating from 8 analysts we track covering the stock, with zero Hold, Sell, or Strong Sell recommendations, reflecting exceptional confidence in the company's growth trajectory. See the ratings
- Barclays’ Julian Mitchell recently issued a Strong Buy rating with a $140.00 price target, representing 29.97% upside potential, following the company's presentation at the Goldman Sachs Industrials and Materials Conference.
- The stock has rallied 158.29% from its 52-week low of $41.71, demonstrating exceptional momentum as investors recognize the company's leverage to AI infrastructure buildout, data center expansion, and broad-based electrification trends.
- Industry ranking context: NVT is currently the 3rd highest-rated stock in the Electrical Equipment & Part industry out of 44 companies, with the industry earning a C rating, positioning nVent as a clear leader in the sector.
- Zen Rating highlights: A (Strong Buy) stocks average +32.52%/yr — the company demonstrates outstanding metrics in several key areas. Let’s dig in…
- Component Grades: Growth and Momentum stand out with A and B ratings respectively, complemented by a B rating in Artificial Intelligence exposure, reflecting the company's strategic positioning to benefit from AI-driven data center infrastructure expansion. See all 7 Zen Component Grades here
_________________________
Tired of Missing Big AI Moves Like Nvidia?
You're not the problem-your trading system is. Tim's XGPT system tracks breaking AI news and shows when to trade. AI-backed. Beginner-friendly. Results proven.
_________________________
2- Kinross Gold Corp (NYSE: KGC)
Did we sell too soon? Despite taking profits of 142% on our Kinross Gold position in the Zen Investor portfolio, the stock’s ascent has continued — soaring nearly 200% off its 52-week lows — powered by strong gold prices, sharp operational execution, and freshly upgraded credit ratings.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $26.95 — get current quote
Max 1-year forecast: $36.00
Why we're watching:
- Recent momentum: Kinross has surged 194% from its 52-week low of $9.00, demonstrating exceptional relative strength in the gold mining sector.
- Credit upgrade catalyst: Moody's recently upgraded Kinross to a Baa2 rating, reflecting improved financial strength and operational performance across the company's global asset base.
- Operational excellence: The company generated $1.1 billion in operating cash flow with a strong 32.5% profit margin, demonstrating effective cost management and operational efficiency.
- Industry ranking context: Kinross Gold currently ranks #11 out of 50 stocks in the Gold industry, which has an Industry Rating of A.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr, putting KGC in a class with top-performing stocks.
- Component Grades: Kinross showcases exceptional performance with Financials (A) and Momentum (A) grades, combined with solid Value (B) and Sentiment (B) ratings, reflecting its strong operational execution and favorable positioning in the gold market. See all 7 Zen Component Grades here
3- MongoDB (NASDAQ: MDB)
MongoDB is riding a wave of AI-driven demand and powerful earnings momentum, triggering a flurry of analyst upgrades and a consensus Strong Buy rating.
Zen Rating: B (Buy) — see full analysis
Recent Price: $416.54 — get current quote
Max 1-year forecast: $525.00
Why we're watching:
- Analyst support: Wall Street consensus is overwhelmingly bullish with 17 Strong Buy ratings, 9 Buy ratings, and 5 Hold ratings from 31 total analysts we track covering the stock. See the ratings
- BMO Capital researcher Keith Bachman (a top 3% rated analyst) recently maintained his Buy rating with a $455 price target following MongoDB's strong quarterly performance.
- Citigroup's Tyler Radke (a top 9% rated analyst) set the Street-high price target of $525, representing over 25% upside potential, reflecting confidence in the company's cloud database growth trajectory.
- Industry ranking context: MongoDB is currently the 11th highest-rated stock out of 125 in the Software Infrastructure industry, which has an Industry Rating of B.
- Zen Rating highlights: Buy (B) stocks average +19.88%/yr — positioning MongoDB among high-quality growth opportunities in the technology sector.
- Component Grades: MongoDB demonstrates exceptional Growth (A) and Sentiment (A) grades, reflecting strong revenue expansion and positive analyst sentiment, while maintaining solid Financials (B) and Momentum (B) scores. See all 7 Zen Component Grades here
4- Eli Lilly & Co (NYSE: LLY)
Exceptional growth is powering this pharma heavyweight as demand for its tirzepatide-based therapies drives a blistering 54% year-over-year revenue surge.
Zen Rating: A (Strong Buy) — see full analysis
Recent Price: $1017.40 — get current quote
Max 1-year forecast: $1,500.00
Why we're watching:
- Analyst support: Wall Street maintains strong conviction with 8 Strong Buy ratings, 3 Buy ratings, and 3 Hold ratings from 14 total analysts we track, reflecting broad confidence in the company's diabetes and obesity franchises. See the ratings
- Morgan Stanley's Terence Flynn (a top 7% rated analyst) recently maintained his Strong Buy rating with a $1,290 price target, citing robust demand from public and private sectors with no signs of severe speculative crowding.
- Leerink Partners' David Risinger (a top 10% rated analyst) upgraded the stock to Buy with a $1,104 price target following strong Q3 results that showed EPS beat of 16.67% and revenue growth of 54% year-over-year.
- Industry ranking context: Eli Lilly is currently the 3rd highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
- Zen Rating highlights: Strong Buy (A) stocks average +32.52%/yr — LLY ranks in this tier, demonstrating exceptional quality across multiple dimensions.
- Component Grades: Lilly showcases outstanding performance with Sentiment (A), Financials (B at 88th percentile), Value (B at 85th percentile), and Growth (B at 90th percentile), reflecting its dominant market position and strong execution. See all 7 Zen Component Grades here
5- Amneal Pharmaceuticals (NASDAQ: AMRX)
A powerful turnaround story is taking shape as strong generics demand, accelerating specialty-drug growth, and rising profitability position Amneal for continued momentum.
Zen Rating: B (Buy) — see full analysis
Recent Price: $12.20 — get current quote
Max 1-year forecast: $15.00
Why we're watching:
- Analyst support: The coverage is small but mighty on WallStreetZen: All 3 analysts we track covering the stock rate it a Strong Buy. See the ratings
- It’s our Stock of the Week: Our Zen Investor Editor in Chief, Steve Reitmeister, recently highlighted AMRX as a stock gaining momentum as strong generics demand, expanding specialty-drug revenue, and rising profitability fuel one of the most compelling turnaround stories in mid-cap pharma. See his full commentary here
- Industry ranking context: Amneal is currently rated #5 of the 57 stocks in the Pharmaceutical industry, which has an Industry Rating of B.
- Zen Rating highlights: Buy (B) stocks historically outperform the market and AMRX's entry into this tier reflects its improving fundamentals, stronger profitability, and more stable growth trajectory.
- Component Grades: Amneal exhibits notable strength with Growth (A), Value (A), and Sentiment (B), supported by rising analyst confidence and accelerating operational execution across all segments. See all 7 Zen Component Grades here
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.